Skip to content

Author

A. Lazar

We have 6 of 69 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

The 2026 World Health Organization Classification of Tumors of Soft Tissue and Bone

The 6th edition of the World Health Organization Classification of Soft Tissue and Bone Tumors (STB6) integrates the latest scientific and molecular discoveries with decades of pathological expertise to establish a globally accepted common language for diagnosis and clinical behavior. In this volume, the “essential” an...

J. Hornick, J. Bovée, C. Antonescu et al. · 0 citations
Open access Oct 2026

Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes.

BACKGROUND Primary breast angiosarcoma (PBA) is rare, and limited data exist because studies often combine primary and secondary angiosarcoma patients. METHODS For patients with PBA who received care at a comprehensive cancer center from 1991 to 2025 and underwent surgical resection, this retrospective study collecte...

Rick D. Vavolizza, A. Subramaniam, Min Yi et al. · 0 citations
Review Sep 2026

Management of Soft Tissue and Visceral Leiomyosarcomas.

Importance Leiomyosarcoma is a rare and heterogeneous malignant mesenchymal neoplasm associated with substantial morbidity and mortality. Given recent advances in biologic understanding and the complexity of leiomyosarcoma, a consensus-driven approach is needed to harmonize management and address remaining clinical and...

F. Campos, R. Gladdy, Annie Achee et al. · 0 citations
Open access Aug 2026

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity

Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...

N. Zacharias, Eric S Rupe, Xinyue Chen et al. · 0 citations
Jul 2026

Abstract A027: Leveraging genomic copy-number complexity in uveal melanoma to drive novel therapeutic development

It is demonstrated that uveal melanoma progression reflects an integrated CN-transcriptional ecosystem extending beyond chromosome 3 loss, with cytoband-level genomic evolution shaping malignant fitness and therapeutic response.

Johnathon L. Rose, Sanjana Srinivasan, A. Cooper et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.